These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 29500813)

  • 1. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
    Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
    J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
    Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.
    Buddhala C; Campbell MC; Perlmutter JS; Kotzbauer PT
    Neurobiol Aging; 2015 Jan; 36(1):476-84. PubMed ID: 25212463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
    Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
    Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.
    Zimmermann M; Fandrich M; Jakobi M; Röben B; Wurster I; Lerche S; Schulte C; Zimmermann S; Deuschle C; Schneiderhan-Marra N; Joos TO; Gasser T; Brockmann K
    J Parkinsons Dis; 2024; 14(7):1405-1416. PubMed ID: 39240648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
    Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.